Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry

D M Shindler; J B Kostis; S Yusuf; M A Quinones; B Pitt; D Stewart; T Pinkett; J K Ghali; A C Wilson

doi:10.1016/s0002-9149(97)89163-1

Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry

Am J Cardiol. 1996 May 1;77(11):1017-20. doi: 10.1016/s0002-9149(97)89163-1.

Authors

D M Shindler¹, J B Kostis, S Yusuf, M A Quinones, B Pitt, D Stewart, T Pinkett, J K Ghali, A C Wilson

Affiliation

¹ University of Medicine and Dentistry-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA.

PMID: 8644628
DOI: 10.1016/s0002-9149(97)89163-1

Abstract

Diabetes is an independent predictor of morbidity and mortality in patients with symptomatic heart failure, patients with asymptomatic left ventricular dysfunction (defined as an ejection fraction of 35% or less), and in a broader registry population with less stringent entry criteria. Although the SOLVD Trials made a major clinical contribution by proving the value of enalapril, diabetes remains a significant predictor of outcome even after adjusting for treatment with enalapril.

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Diabetes Complications*
Diabetes Mellitus / mortality
Enalapril / therapeutic use
Female
Heart Failure / complications*
Heart Failure / drug therapy
Humans
Male
Multicenter Studies as Topic
Odds Ratio
Prognosis
Randomized Controlled Trials as Topic
Registries
Regression Analysis
Risk Factors
Ventricular Dysfunction, Left / complications*
Ventricular Dysfunction, Left / drug therapy
Ventricular Dysfunction, Left / mortality

Substances

Angiotensin-Converting Enzyme Inhibitors
Enalapril